Evolus Stock (NASDAQ:EOLS)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$10.87

52W Range

$9.80 - $17.82

50D Avg

$14.11

200D Avg

$13.58

Market Cap

$689.57M

Avg Vol (3M)

$599.39K

Beta

1.31

Div Yield

-

EOLS Company Profile

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

322

IPO Date

Feb 08, 2018

Website

EOLS Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 23	Dec 22	Dec 21
Product	$199.72M	$146.59M	$98.97M
Service	$2.36M	$2.02M	-

Fiscal year ends in Dec 23 | Currency in USD

EOLS Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$199.72M	$148.62M	$99.67M
Operating Income	$-49.23M	$-57.58M	$-63.62M
Net Income	$-61.69M	$-74.41M	$-46.81M
EBITDA	$-70.21M	$-59.50M	$-64.28M
Basic EPS	-	$-1.33	$-0.94
Diluted EPS	-	$-1.33	$-0.94

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q3 24Nov 06, 24 | 7:28 PM

Q2 24Jul 31, 24 | 10:22 PM

Q1 24May 07, 24 | 12:00 AM

Peer Comparison

Ticker	Company
PAHC	Phibro Animal Health Corporation
SUPN	Supernus Pharmaceuticals, Inc.
ITCI	Intra-Cellular Therapies, Inc.
ANIP	ANI Pharmaceuticals, Inc.
IXHL	Incannex Healthcare Limited
PROC	Procaps Group S.A.
PCRX	Pacira BioSciences, Inc.
PBH	Prestige Consumer Healthcare Inc.
ALKS	Alkermes plc
COLL	Collegium Pharmaceutical, Inc.
AMPH	Amphastar Pharmaceuticals, Inc.